Lataa...
PARP inhibitors for Homologous Recombination- Deficient Prostate Cancer
INTRODUCTION: Prostate adenocarcinoma represents a leading cause of cancer-related mortality. Increased emphasis on understanding the molecular basis of prostate cancer has identified a substantial burden of homologous recombination (HR) pathway mutations, which are enriched in castrate-resistant di...
Tallennettuna:
| Julkaisussa: | Expert Opin Emerg Drugs |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6088797/ https://ncbi.nlm.nih.gov/pubmed/29595348 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14728214.2018.1459563 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|